SARS-CoV-2, the causative agent of COVID-19, has caused more than 60 million cases worldwide with almost 1.5 million deaths as of November 2020. Repurposing existing drugs is the most rapid path to clinical intervention for emerging diseases. ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged virus that causes coronavirus infectious disease 2019 (COVID-19). SARS-CoV-2 spike protein, like SARS-CoV-1, uses the angiotensin converting enzyme 2 (ACE2) as a cellular receptor to initiate infection. Compounds that interfere with the SARS-CoV-2 spike protein receptor binding domain protein (RBD)-ACE2 receptor interaction may function as entry inhibitors. Here, we used a dual strategy of molecular docking and surface plasmon resonance (SPR) screening of compound libraries to identify those that bind to human ACE2 or the SARS-CoV-2 spike protein receptor binding domain (RBD). Molecular modeling screening interrogated 57,641 compounds and focused on the region of ACE2 that is engaged by RBD of the SARS-CoV-2 spike glycoprotein and vice versa. SPR screening used immobilized human ACE2 and SARS-CoV-2 Spike protein to evaluate the binding of these proteins to a library of 3,141 compounds. These combined screens identified compounds from these libraries that bind at K D (equilibrium dissociation constant) <3 μM affinity to their respective targets, 17 for ACE2 and 6 for SARS-CoV-2 RBD. Twelve ACE2 binders and six of the RBD binders compete with the RBD-ACE2 interaction in an SPR-based competition assay. These compounds included registered drugs and dyes used in biomedical applications. A Vero-E6 cell-based SARS-CoV-2 infection assay was used to evaluate infection blockade by candidate entry inhibitors. Three compounds demonstrated dose-dependent antiviral in vitro potency—Evans blue, sodium lifitegrast, and lumacaftor. This study has identified potential drugs for repurposing as SARS-CoV-2 entry inhibitors or as chemical scaffolds for drug development.
【저자키워드】 SARS-CoV-2, ACE2, Drug screening, 【초록키워드】 COVID-19, severe acute respiratory syndrome coronavirus 2, coronavirus, Diseases, Antiviral, Drug development, spike, sodium, SARS-COV-2 infection, angiotensin converting enzyme 2, spike glycoprotein, Infection, molecular docking, repurposing, Intervention, drug, Infectious disease, in vitro, surface plasmon resonance, severe acute respiratory syndrome Coronavirus, virus, SPR, SARS-CoV-1, angiotensin converting enzyme, Spike protein, Receptor binding domain, human ACE2, Protein, RBD, SARS-CoV-2 spike glycoprotein, SARS-CoV-2 spike protein, death, targets, receptor, respiratory, entry inhibitors, inhibitor, binding, compounds, Dissociation constant, Interaction, angiotensin, SARS-CoV-2 RBD, dual, causative agent, lumacaftor, lifitegrast, acute respiratory syndrome, surface plasmon, acute respiratory syndrome coronavirus, enzyme, SARS-CoV-2 entry, Compound, SARS-CoV-2 spike protein receptor binding domain, Evans blue, Registered, blockade, these compounds, library, cellular receptor, RBD binders, VERO-E6, RBD-ACE2, identify, was used, evaluate, caused, demonstrated, the RBD, interfere, cause, dose-dependent, the SARS-CoV-2, 【제목키워드】 spike, Human, Spike protein, Compound, candidate, block, bind,